

Contains Nonbinding Recommendations
Draft Guidance on Maraviroc

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Maraviroc

Form/Route: Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, two-way crossover *in vivo*
Strength: 300 mg
Subjects: Healthy males and non-pregnant females, general population.
Additional Comments:

2. Type of study: Fed
Design: Single-dose, two-way crossover *in vivo*
Strength: 300 mg
Subjects: Healthy males and non-pregnant females, general population.
Additional Comments:

Analytes to measure (in appropriate biological fluid): Maraviroc in plasma.

Bioequivalence based on (90% CI): Maraviroc

Waiver request of *in-vivo* testing: 150 mg based on (i) acceptable bioequivalence studies on the 300 mg strength, (ii) proportional similarity of the 150 and 300 mg strengths, and (iii) acceptable *in vitro* dissolution testing of the 150 mg and 300 mg strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative drug dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.